Levi Diagnostics, Inc. is a research and development startup specializing in the application of nanotechnology innovations.
The company was incorporated at the end of 2019, with a mission of delivering revolutionary nanosensor technologies to government agencies, private sector clients, and consumers.
Using the same proprietary scientific platform we focus our efforts on three major areas:
Rapid viral diagnostics,
Women’s diseases diagnostics.
COVID-19 – LD RAPID TEST
Cases of COVID-19 are increasing exponentially, thus increasing government and industry initiatives to fight the virus. This will lead to a rise in the global COVID-19 detection kits market size from 2020 to 2026.
According to a research report put forth by Global Market Insights, Inc., the market size is valued at USD 3.3 billion and is expected to witness 17.3% CAGR from 2020 to 2026, potentially reaching USD 8 billion.
The diagnostic centers’ segment accounted for approximately 32% of the market share in 2020, according to the report.
WOMEN DISEASES DIAGNOSTICS
NARCOTICS DIGITAL SWEAT ANALYZER
Narcotics abuse in the United States has now reached epidemic proportions (commonly called “the opioid crisis”).
Last year, drug overdoses killed 70,980 Americans. The AMA (American Medical Association) is greatly concerned by an increasing number of reports from national, state, and local media suggesting increases in opioid and other drug-related mortality — particularly deaths from illicitly manufactured synthetic narcotics such as fentanyl and fentanyl analogs.
WOMEN'S DISEASES DIAGNOSTICS
There is a vast, unexplored area of using menstrual blood for women’s health and disease diagnostics. Menstrual blood, which contains a variety of organic and inorganic compounds, such as salts, metabolites, hormones, enzymes, antibodies, and pathogens, is a rich source of information. Physiological and pathological changes lead to changes in these components. Thus, the composition of menstrual blood is an efficient indicator of women's physiology and diseases. This natural blood test is far more precise and specific than that of normal blood.
WHO WE ARE
As a subsidiary of Emitech, Inc. (emitechinc.com), we are able to leverage a combined 20 years of experience in the field
of nanotechnologies for various sensing applications. Emitech has had successful results working both with government grants and private sector investors.
We have multiple US patents for the design and implementation of high-sensitivity detection technologies.